Growth Hormone Secretagogues: CJC-1295, Ipamorelin, and Sermorelin Compared

GHRH vs. Ghrelin: Two Pathways to GH Release

Growth hormone secretion from the anterior pituitary is controlled by two opposing signals: GHRH (growth hormone-releasing hormone) tells the pituitary to release GH, while somatostatin tells it to stop. A third signal, ghrelin, provides an independent stimulatory input through a completely different receptor.

This dual control system is why combining a GHRH analog with a ghrelin mimetic produces a synergistic effect — you're stimulating GH release through two independent pathways simultaneously. Neither pathway alone produces as strong a response as both together.

Understanding this distinction is key to understanding why CJC-1295/Sermorelin and Ipamorelin aren't redundant even though they all "increase GH." They do it through different mechanisms.

CJC-1295

CJC-1295 is a synthetic analog of GHRH (growth hormone-releasing hormone) with 29 amino acids. It exists in two forms:

CJC-1295 with DAC (Drug Affinity Complex)

The DAC modification allows CJC-1295 to bind to albumin in the bloodstream, dramatically extending its half-life to approximately 6-8 days. This means it provides a sustained elevation of baseline GH levels rather than discrete pulses. The advantage: once or twice weekly dosing. The concern: the loss of natural GH pulsatility may reduce the physiological benefits compared to pulsatile release.

CJC-1295 without DAC (also called Modified GRF 1-29)

Without the DAC modification, half-life drops to about 30 minutes. This produces a sharp GH pulse that mimics natural physiology more closely. The tradeoff: you need to dose 2-3 times daily for full effect. Most research protocols pair this form with Ipamorelin for the synergistic pulse.

Ipamorelin

Ipamorelin is a pentapeptide (5 amino acids) that acts as a selective ghrelin receptor agonist. It was specifically designed to stimulate GH release with minimal side effects — and it delivers on that design goal remarkably well.

Unlike GHRP-6 (which causes intense hunger through ghrelin receptor activation in the gut) and GHRP-2 (which can elevate cortisol and prolactin), Ipamorelin stimulates GH release without significantly affecting other hormones. It's the cleanest GH secretagogue available, which is why it's become the default choice in most research protocols.

Typical research dose: 100-300 mcg, administered 2-3 times daily on an empty stomach. The GH pulse peaks approximately 30-40 minutes after injection.

Sermorelin

Sermorelin is a 29-amino-acid peptide that represents the bioactive portion of natural GHRH. It's the oldest of the three — it was FDA-approved in 1997 for diagnostic testing of pituitary GH secretion and was used clinically for pediatric growth hormone deficiency (under the brand name Geref).

Sermorelin's clinical history gives it an advantage in terms of human safety data. We actually have published human pharmacokinetic and safety profiles, which is more than can be said for CJC-1295 or Ipamorelin.

The tradeoff: Sermorelin has a very short half-life (10-20 minutes) and may be less potent than CJC-1295 at equivalent doses. It also shows some desensitization with chronic use — the GH response may diminish over weeks of continuous use.

Side-by-Side Comparison

The Classic Stack: CJC-1295 + Ipamorelin

The most popular GH secretagogue protocol combines CJC-1295 (no DAC) at 100 mcg with Ipamorelin at 100-200 mcg, injected together 2-3 times daily on an empty stomach. The CJC-1295 amplifies the GH pulse while Ipamorelin triggers it.

Timing matters: inject at least 2-3 hours after eating and wait 30 minutes before eating after injection. Blood glucose and insulin blunt the GH response. Most researchers dose upon waking (fasted) and at bedtime.

For more on combining peptides, see our peptide stacking guide.